MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: 22UA Forum: Aktien User: Thekla

luc ja so ist es

also chillen wir weiter

fosun ,,,also grund fur anstig der aktie haute waren pfizer pillen > Fosun Pharma unterzeichnet Vereinbarung mit The Medicines Patent Pool (MPP) zur Herstellung einer kostengünstigen generischen Version von Nirmatrelvir zur oralen COVID-19-Behandlung von Pfizer in Kombination mit Ritonavir zur Lieferung in 95 Länder mit niedrigem und mittlerem Einkomme

Genau Swen 👍🏻 Fosun hat am Freitag eine Vereinbarung erzielt Paxlovid als Generika herzustellen

Link vergessen: https://www.hindustantimes.com/world-news/alert-for-china-as-data-reveals-sinovac-vaccine-less-effective-for-elderly-101647847994211-amp.html

Alert for China as data reveals Sinovac vaccine less effective for elderly Data indicating the Sinovac Biotech Ltd. Covid-19 vaccine is less effective than an mRNA vaccine. It’s a concerning trend for mainland China, which hasn’t approved an mRNA shot and where only half of the population aged 80 and older are fully vaccinated. Data indicating the Sinovac Biotech Ltd. Covid-19 vaccine is less effective than an mRNA vaccine at preventing death in elderly people in Hong Kong is a red flag for mainland China, where infections are climbing and a vast swathe of the population is inoculated with the inactivated shot. Almost 3% of people aged 80 or older who got two doses of the inactivated CoronaVac shot died after getting infected, compared with 1.5% of those who were given the BioNTech SE vaccine, according to a preliminary analysis conducted by the Centre for Health Protection. Getting just one dose of either offered less protection, with 5.8% of those given CoronaVac and 3.4% of those given the mRNA shot subsequently dying. The data is based on the first 5,435 deaths in the current outbreak and showed that the overall fatality rate was just 0.09% for those who had gotten two vaccine doses regardless of age. Hong Kongers can pick between the two vaccines, and about 80% of its oldest residents have received Sinovac. The group as a whole remains severely under-vaccinated and accounts for more than 70% of total deaths. Sinovac didn’t immediately respond to requests for comment via telephone and WeChat. It’s a concerning trend for mainland China, which hasn’t approved an mRNA shot and where only half of the population aged 80 and older are fully vaccinated. The nation is already grappling to contain its worst outbreak in two years without causing severe disruptions to its economic growth, even as officials turn to typical Covid Zero measures like mass testing and strict lockdowns. The prospect of elderly people lacking sufficient protection through vaccination risks further delaying the reopening of the world’s second largest economy. Over the weekend, the country reported is first Covid deaths in more than a year: a man in his 60s and another in his 80s, one of whom was unvaccinated. Mainland China is also keen to avoid repeating the missteps of Hong Kong, where daily cases spiraled to more than 50,000 and overwhelmed health-care resources. The city had to treat people outside hospitals, while local media reported body bags were left next to patients’ beds as mortuaries reached capacity. Chinese officials recently pleaded for the country’s elderly to get their Covid shots and cited high fatality rate among the unvaccinated and elderly elsewhere, especially in Hong Kong, as cautionary tales. Officials pledged to reach out to key groups and nursing homes to address the concern they have on the safety and effect of Covid vaccines. Still, the figures show either vaccine was dramatically better than nothing at all. Among those aged 80 and older, 15% of those who weren’t immunized died after contracting the virus. The government released the information after local newspaper Ming Pao reported on immunization rates among the city’s fatalities.

https://www.tagesschau.de/newsticker/liveblog-corona-sonntag-135.html

fosun---- SHANGHAI CHINA, 18. März 2022 – Shanghai Fosun Pharmaceutical (Group) Co., Ltd. („Fosun Pharma“ oder „Group“; Börsenkürzel: 600196.SH, 02196.HK) gab bekannt, dass Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. („Fosun Pharmaceutical Industrial“), eine Tochtergesellschaft von Fosun Pharma, hat eine Unterlizenzvereinbarung mit dem Medicines Patent Pool (MPP) unterzeichnet, um die generische Version von Pfizers oralem COVID-19-Behandlungsmittel Nirmatrelvir herzustellen, das mitverpackt ist mit einer niedrigen Ritonavir-Dosis, kann in 95 Ländern mit niedrigem und mittlerem Einkommen (LMICs) geliefert werden, die etwa 53 % der Weltbevölkerung ausmachen.

Guten Morgen 👋 Ist es jetzt zu spät, BioNTech-Aktien zu kaufen? 21.03.22, 08:56 Fool.de In 3 Sätzen BioNTech verdient eine Menge Geld mit seinem Anteil an den Gewinnen von Comirnaty. In diesem Jahr dürften keine neuen Medikamente auf den Markt gebracht werden. Wer die Aktie jetzt kauft, muss möglicherweise noch eine Weile warten, bis sich der Kauf auszahlt. https://www.onvista.de/news/ist-es-jetzt-zu-spaet-biontech-aktien-zu-kaufen-528204861

Nächste Woche oder nicht, Luciman? 28.3.

ahh luciman daher weht der Wind. Haben die Chinesen sich heimlich mit Fubitai impfen lassen?

Morgen kommen bei Fosun Pharmaceutical auch Quartalszahlen,hoffentlich verbunden mit den von uns erhofften Nachricht 👌🏻

Oh,Oh, Was für eine Kehrtwende? Und die Menschenrechte??? https://www.finanzen100.de/finanznachrichten/boerse/gas-von-den-scheichs-statt-von-putin-wer-jetzt-auf-katar-setzt-macht-grossen-fehler_H1809122577_64322201/

Habe die Shanghai Fosun in die "Marktübersicht " aufgenommen 4,60 € +18,67%

Moin Moin Mario ☕️👋☘️☘️

… danke Thekla, wie so oft, sehr nützliche Infos von dir 👌🏼